Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Pediatric Blood & Cancer|September 8, 2022
Multidisciplinary Network ActiveOncoKids guidelines for providing movement and exercise in pediatric oncology: Consensus-based recommendationsMiriam Götte, Gabriele Gauß, Uta Dirksen, et al.
Cancer Treatment Reviews|March 17, 2010
The role of the 'innovative therapies for children with cancer' (ITCC) European consortiumC Michel Zwaan, Pamela Kearns, Huib Caron, et al.
Anti-Cancer Drugs|February 16, 2005
Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantationDoris Oechtering, Brunhild Schiltmeyer, Georg Hempel, et al.
Pediatric Blood & Cancer|September 5, 2009
Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocolGeorg Hempel, Mary V Relling, Giulio de Rossi, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2016
Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trialMiriam Krischke, Georg Hempel, Swantje Völler, et al.
Pediatric Blood & Cancer|February 21, 2008
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trialThomas Klingebiel, Joachim Boos, Florian Beske, et al.
Cancer Chemotherapy and Pharmacology|June 18, 2003
Population pharmacokinetics of oral busulfan in childrenBrunhild Schiltmeyer, Thomas Klingebiel, Matthias Schwab, et al.
Haematologica|August 24, 2014
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemiaWing H Tong, Rob Pieters, Hester A de Groot-Kruseman, et al.
Blood|September 24, 2011
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trialsAndrea Willer, Joachim Gerss, Thorsten König, et al.
The Lancet. Oncology|September 1, 2005
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trialFrank Berthold, Joachim Boos, Stefan Burdach, et al.
Pageof 10